Resveratrol-A boon for treating Alzheimer's disease?

Brain Research Reviews

Volumn 52, Issue 2, 2006, Pages 316-326

  Anekonda, Thimmappa S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Calorie restriction; Resveratrol; Sirtuins

Indexed keywords

HISTONE DEACETYLASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTEASOME; REACTIVE OXYGEN METABOLITE; RESVERATROL; SILENT INFORMATION REGULATOR PROTEIN 2; SIRTUIN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BRAIN ISCHEMIA; CALCIUM HOMEOSTASIS; CALORIC RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG METABOLISM; EPILEPSY; HUMAN; HUNTINGTON CHOREA; NERVE CELL NECROSIS; NERVE FIBER DEGENERATION; NERVE FIBER TRANSECTION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEQUENCE HOMOLOGY; STROKE; TREATMENT OUTCOME; VASODILATATION;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIOXIDANTS; BRAIN; CALORIC RESTRICTION; HUMANS; NERVE DEGENERATION; REACTIVE OXYGEN SPECIES; SIRTUINS; STILBENES;

EID: 33747886389     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2006.04.004     Document Type: Review

References (119)

1. Allain H., Bentue-Ferrer D., Tribut O., Gauthier S., Michel B.F., and Drieu-La Rochelle C. Alzheimer's disease: the pharmacological pathway. Fundam. Clin. Pharmacol. 17 (2003) 419-428
2. Anandatheerthavarada H.K., Biswas G., Robin M.A., and Avadhani N.G. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J. Cell Biol. 161 (2003) 41-54
3. Anekonda T.S., and Reddy P.H. Can plants provide a new generation of drugs for treating Alzheimer's disease?. Brain Res. Brain Res. Rev. 50 (2005) 361-376
4. Anekonda T.S., and Reddy P.H. Neuronal protection by sirtuins in Alzheimer's disease. J. Neurochem. 96 (2006) 305-313
5. Ang-Lee M.K., Moss J., and Yuan C.S. Herbal medicines and perioperative care. JAMA 286 (2001) 208-216
6. Arai K., Nishiyama N., Matsuki N., and Ikegaya Y. Neuroprotective effects of lipoxygenase inhibitors against ischemic injury in rat hippocampal slice cultures. Brain Res. Brain Res. Rev. 904 (2001) 167-172
7. Araki T., Sasaki Y., and Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305 (2004) 1010-1013
8. Barthelemy C., Henderson C.E., and Pettmann B. Foxo3a induces motoneuron death through the Fas pathway in cooperation with JNK. BMC Neurosci. 5 (2004) 48
9. Bastianetto S., and Quirion R. Natural antioxidants and neurodegenerative diseases. Front Biosci. 9 (2004) 3447-3452
10. Bastianetto S., Zheng W.H., and Quirion R. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br. J. Pharmacol. 131 (2000) 711-720
11. Bedalov A., and Simon J.A. Neuroscience. NAD to the rescue. Science 305 (2004) 954-955 (Erratum in: Science 308 (2005) 633)
12. Bedalov A., Gatbonton T., Irvine W.P., Gottschling D.E., and Simon J.A. Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 15113-15118
13. Bellizzi D., Rose G., Cavalcante P., Covello G., Dato S., De Rango F., Greco V., Maggiolini M., Feraco E., Mari V., Franceschi C., Passarino G., and De Benedictis G. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics 85 (2005) 258-263
14. Blander G., and Guarente L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73 (2004) 417-435
15. Bluher M., Kahn B.B., and Kahn C.R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299 (2003) 572-574
16. Bordone L., and Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat. Rev., Mol. Cell Biol. 6 (2005) 298-305
17. Borra M.T., Smith B.C., and Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280 (2005) 17187-17195
18. Chalimoniuk M., Glowacka J., Zabielna A., Eckert A., and Strosznajder J.B. Nitric oxide alters arachidonic acid turnover in brain cortex synaptoneurosomes. Neurochem. Int. 48 (2006) 1-8
19. Chen J., Zhou Y., Mueller-Steiner S., Chen L.F., Kwon H., Yi S., Mucke L., and Gan L. SIRT1 protects against microglia-dependent beta amyloid toxicity through inhibiting NF-kappa B signaling. J. Biol. Chem. 280 (2005) 40364-40374
20. Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B., Kessler B., Howitz K.T., Gorospe M., de Cabo R., and Sinclair D.A. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305 (2004) 390-392
21. de la Lastra C.A., and Villegas L. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res. 49 (2005) 405-430
22. de la Monte S.M., and Wands J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimer's Dis. 7 (2005) 45-61
23. Denu J.M. Linking chromatin function with metabolic networks: Sir2 family of NAD(C)-dependent deacetylases. Trends Biochem. Sci. 28 (2003) 41-48
24. de Vrij F.M., Fischer D.F., van Leeuwen F.W., and Hol E.M. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog. Neurobiol. 74 (2004) 249-270
25. Dirks A.J., and Leeuwenburgh C. Caloric restriction in humans: potential pitfalls and health concerns. Mech. Ageing Dev. 127 (2006) 1-7
26. Duncan A.M., Phipps W.R., and Kurzer M.S. Phyto-oestrogens. Best Pract Res. Clin. Endocrinol. Metab. 17 (2003) 253-271
27. Flachsbart F., Croucher P.J., Nikolaus S., Hampe J., Cordes C., Schreiber S., and Nebel A. Sirtuin 1 (SIRT1) sequence variation is not associated with exceptional human longevity. Exp. Gerontol. 41 (2006) 98-102
28. Flood F., Murphy S., Cowburn R.F., Lannfelt L., Walker B., and Johnston J.A. Proteasome-mediated effects on amyloid precursor protein processing at the gamma-secretase site. Biochem. J. 385 Pt 2 (2005) 545-550
29. Fremont L., Belguendouz L., and Delpal S. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci. 64 (1999) 2511-2521
30. Frye R.A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun. 260 (1999) 273-279
31. Frye R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273 (2000) 793-798
32. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
33. Gan L., Han Y., Bastianetto S., Dumont Y., Unterman T.G., and Quirion R. FoxO-dependent and -independent mechanisms mediate SirT1 effects on IGFBP-1 gene expression. Biochem. Biophys. Res. Commun. 337 (2005) 1092-1096
34. Gao Z.B., and Hu G.Y. Trans-resveratrol, a red wine ingredient, inhibits voltage-activated potassium currents in rat hippocampal neurons. Brain Res. 1056 (2005) 68-75
35. Gentile M.T., Vecchione C., Maffei A., Aretini A., Marino G., Poulet R., Capobianco L., Selvetella G., and Lembo G. Mechanisms of soluble beta-amyloid impairment of endothelial function. J. Biol. Chem. 279 (2004) 48135-48142
36. Gilley J., Coffer P.J., and Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J. Cell Biol. 162 (2003) 613-622
37. Glaser V. Billion-dollar market blossoms as botanicals take root. Nat. Biotechnol. 17 (1999) 17-18
38. Grozinger C.M., Chao E.D., Blackwell H.E., Moazed D., and Schreiber S.L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276 (2001) 38837-38843
39. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 14 (2000) 1021-1026
40. Guix F.X., Uribesalgo I., Coma M., and Munoz F.J. The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol. 76 (2005) 126-152
41. Gupta Y.K., Briyal S., and Chaudhary S. Protective effect of trans-resveratrol against kainic acid-induced seizures and oxidative stress in rats. Pharmacol. Biochem. Behav. 71 (2002) 245-249
42. Han Y.S., Zheng W.H., Bastianetto S., Chabot J.G., and Quirion R. Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br. J. Pharmacol. 141 (2004) 997-1005
43. Hol E.M., van Leeuwen F.W., and Fischer D.F. The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B(+1). Trends Mol. Med. 11 (2005) 488-495
44. Howes M.J., and Houghton P.J. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol. Biochem. Behav. 75 (2003) 513-527
45. Howes M.J., Perry N.S., and Houghton P.J. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother. Res. 17 (2003) 1-18
46. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., and Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425 (2003) 191-196
47. Huang S.S., Tsai M.C., Chih C.L., Hung L.M., and Tsai S.K. Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia. Life Sci. 69 (2001) 1057-1065
48. Jang J.H., and Surh Y.J. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radical Biol. Med. 34 (2003) 1100-1110
49. Kaeberlein M., McDonagh T., Heltweg B., Hixon J., Westman E.A., Caldwell S.D., Napper A., Curtis R., DiStefano P.S., Fields S., Bedalov A., and Kennedy B.K. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 280 (2005) 17038-17045
50. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., and LaFerla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25 (2005) 8843-8853
51. Krebs N.F. Bioavailability of dietary supplements and impact of physiologic state: infants, children and adolescents. J. Nutr. 31 Suppl. 4 (2001) 1351S-1354S (Apr.)
52. Kriem B., Sponne I., Fifre A., Malaplate-Armand C., Lozac'h-Pillot K., Koziel V., Yen-Potin F.T., Bihain B., Oster T., Olivier J.L., and Pillot T. Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. FASEB J. 19 (2005) 85-87
53. Kuzmichev, Margueron R., Vaquero A., Preissner T.S., Scher M., Kirmizis A., Ouyang X., Brockdorff N., Abate-Shen C., Farnham P., and Reinberg D. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 1859-1864
54. Lamming D.W., Wood J.G., and Sinclair D.A. Small molecules that regulate lifespan: evidence for xenohormesis. Mol. Microbiol. 53 (2004) 1003-1009
55. Langley E., Pearson M., Faretta M., Bauer U.M., Frye R.A., Minucci S., Pelicci P.G., and Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21 (2002) 2383-2396
56. Lazarov O., Robinson J., Tang Y.P., Hairston I.S., Korade-Mirnics Z., Lee V.M., Hersh L.B., Sapolsky R.M., Mirnics K., and Sisodia S.S. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120 (2005) 701-713
57. Leslie C.C. Properties and regulation of cytosolic phospholipase A2. J. Biol. Chem. 272 (1997) 16709-16712
58. Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., Trinchese F., Liu S., Gunn-Moore F., Lue L.F., Walker D.G., Kuppusamy P., Zewier Z.L., Arancio O., Stern D., Yan S.S., and Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304 (2004) 448-452
59. Marambaud P., Zhao H., and Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-{beta} peptides. J. Biol. Chem. 280 (2005) 37377-37382
60. McGeer P.L., and McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 21 (1995) 195-218
61. Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., and Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell 16 (2005) 4623-4635
62. Monsonego A., and Weiner H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 302 (2003) 834-838
63. Morelli V., and Naquin C. Alternative therapies for traditional disease states: menopause. Am. Fam. Physician 66 (2002) 129-134
64. Mostoslavsky R., Chua K.F., Lombard D.B., Pang W.W., Fischer M.R., Gellon L., Liu P., Mostoslavsky G., Franco S., Murphy M.M., Mills K.D., Patel P., Hsu J.T., Hong A.L., Ford E., Cheng H.L., Kennedy C., Nunez N., Bronson R., Frendewey D., Auerbach W., Valenzuela D., Karow M., Hottiger M.O., Hursting S., Barrett J.C., Guarente L., Mulligan R., Demple B., Yancopoulos G.D., and Alt F.W. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124 (2006) 315-329
65. Nanji A.A., and French S.W. Alcoholic beverages and coronary heart disease. Atherosclerosis 60 (1986) 197-198
66. Nijveldt R.J., van Nood E., van Hoorn D.E., Boelens P.G., van Norren K., and van Leeuwen P.A. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74 (2001) 418-425
67. Nisoli E., Tonello C., Cardile A., Cozzi V., Bracale R., Tedesco L., Falcone S., Valerio A., Cantoni O., Clementi E., Moncada S., and Carruba M.O. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 310 (2005) 314-317
68. North B.J., and Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylates. Genome Biol. 5 (2005) 224
69. North B.J., Marshall B.L., Borra M.T., Denu J.M., and Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+ dependent tubulin deacetylase. Mol. Cell 11 (2003) 437-444
70. Oh S., Hong H.S., Hwang E., Sim H.J., Lee W., Shin S.J., and Mook-Jung I. Amyloid peptide attenuates the proteasome activity in neuronal cells. Mech. Ageing Dev. 126 (2005) 1292-1299
71. Pacifici G.M. Inhibition of human liver and duodenum sulfotransferases by drugs and dietary chemicals: a review of the literature. Int. J. Clin. Pharmacol. Ther. 42 (2004) 488-495
72. Pagans S., Pedal A., North B.J., Kaehlcke K., Marshall B.L., Dorr A., Hetzer-Egger C., Henklein P., Frye R., McBurney M.W., Hruby H., Jung M., Verdin E., and Ott M. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol. 3 (2005) e41
73. Parker J.A., Arango M., Abderrahmane S., Lambert E., Tourette C., Catoire H., and Neri C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 37 (2005) 349-350 (Erratum in: Nat Genet. 37, 555)
74. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J. 17 (2003) 1975-1985
75. Picard, Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., Leid M., McBurney M.W., and Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429 (2004) 771-776 (Erratum in: Nature 430, 921)
76. Porcu M., and Chiarugi A. The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol. Sci. 26 (2005) 94-103
77. Qing, Zhou W., Christensen M.A., Sun X., Tong Y., and Song W. Degradation of BACE by the ubiquitin-proteasome pathway. FASEB J. 18 (2004) 1571-1573
78. Qiu W.Q., and Folstein F.M. Insulin, insulin-degrading enzyme and amyloid-b peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging 27 (2006) 190-198
79. Raber J. Androgens, apoE, and Alzheimer's disease. Sci. Aging Knowledge Environ. (2004) re2
80. Raber J., Huang Y., and Ashford J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 25 (2004) 641-650
81. Raskin I., Ribnicky D.M., Komarnytsky S., Llic N., Poulev A., Borisjuk N., Brinker A., Moreno D.A., Ripoll C., Yakoby N., O'Neil J.M., Cornwell T., Pastor I., and Fridlender B. Plants and human health in the twenty-first century. Trends Biotechol. 20 (2002) 522-531
82. Reddy P.H., and Beal M.F. Are mitochondria critical in the pathogenesis of Alzheimer's disease?. Brain Res. Brain Res. Rev. 49 (2005) 618-632
83. Rose G., Dato S., Altomare K., Bellizzi D., Garasto S., Greco V., Passarino G., Feraco E., Mari V., Barbi C., BonaFe M., Franceschi C., Tan Q., Boiko S., Yashin A.I., and De Benedictis G. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp. Gerontol. 38 (2005) 1065-1070
84. Russo A., Palumbo M., Aliano C., Lempereur L., Scoto G., and Renis M. Red wine micronutrients as protective agents in Alzheimer like induced insult. Life Sci. 72 (2003) 2369-2379
85. Savaskan E., Olivieri G., Meier F., Seifritz E., Wirz-Justice A., and Muller-Spahn F. Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology 49 (2003) 380-383
86. Seidman M., Babu S., Tang W., Naem E., and Quirk W.S. Effects of resveratrol on acoustic trauma. Otolaryngol. Head Neck Surg. 129 (2003) 463-470
87. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
88. Selkoe D.J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 6 (2004) 1054-1061
89. Senawong T., Peterson V.J., and Leid M. BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression. Arch. Biochem. Biophys. 434 (2005) 316-325
90. Sharma M., and Gupta Y.K. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci. 71 (2002) 2489-2498
91. Shi T., Wang F., Stieren E., and Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J. Biol. Chem. 280 (2005) 13560-13567
92. Sinclair D.A. Toward a unified theory of caloric restriction and longevity regulation. Mech. Ageing Dev. 126 (2005) 987-1002
93. Sinha K., Chaudhary G., and Gupta Y.K. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci. 71 (2002) 655-665
94. Song S., Kim S.Y., Hong Y.M., Jo D.G., Lee J.Y., Shim S.M., Chung C.W., Seo S.J., Yoo Y.J., Koh J.Y., Lee M.C., Yates A.J., Ichijo H., and Jung Y.K. Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol. Cell 12 (2003) 553-563
95. Song M.S., Saavedra L., and de Chaves E.L. Apoptosis is secondary to non-apoptotic axonal degeneration in neurons exposed to Abeta in distal axons. Neurobiol. Aging (2005) (Aug 22; [Electronic publication ahead of print])
96. Tamagno E., Bardini P., Obbili A., Vitali A., Borghi R., Zaccheo D., Pronzato M.A., Danni O., Smith M.A., Perry G., and Tabaton M. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 10 (2002) 279-288
97. Tamagno E., Guglielmotto M., Bardini P., Santoro G., Davit A., Di Simone D., Danni O., and Tabaton M. Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. Neurobiol. Dis. 14 (2003) 291-301
98. Tamagno E., Parola M., Bardini P., Piccini A., Borghi R., Guglielmotto M., Santoro G., Davit A., Danni O., Smith M.A., Perry G., and Tabaton M. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J. Neurochem. 92 (2005) 628-636
99. Tang B.L. Alzheimer's disease: channeling APP to non-amyloidogenic processing. Biochem. Biophys. Res. Commun. 331 (2005) 358-375
100. Tanzi R.E., and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120 (2005) 545-555
101. Tchantchou F., Graves M., Rogers E., Ortiz D., and Shea T.B. N-acteyl cysteine alleviates oxidative damage to central nervous system of ApoE-deficient mice following folate and vitamin E-deficiency. J. Alzheimers Dis. 7 (2005) 135-138
102. Tesch B.J. Herbs commonly used by women. Am. J. Obstet. Gynecol. 188 (2003) S44-S55
103. Tissenbaum H.A., and Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410 (2001) 227-230
104. Virgili M., and Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci. Lett. 281 (2000) 123-126
105. Vitaglione P., Sforza S., Galaverna G., Ghidini C., Caporaso N., Vescovi P.P., Fogliano V., and Marchelli R. Bioavailability of trans-resveratrol from red wine in humans. Mol. Nutr. Food Res. 49 (2005) 495-504
106. Walle T., Hsieh F., DeLegge M.H., Oatis Jr. J.E., and Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32 (2004) 1377-1382
107. Wallerath T., Li H., Godtel-Ambrust U., Schwarz P.M., and Forstermann U. A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide 12 (2005) 97-104
108. Walsh D.M., Townsend M., Podlisny M.B., Shankar G.M., Fadeeva J.V., Agnaf O.E., Hartley D.M., and Selkoe D.J. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J. Neurosci. 25 (2005) 2455-2462
109. Wang M.J., Huang H.M., Hsieh S.J., Jeng K.C., and Kuo J.S. Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J. Neuroimmunol. 112 (2001) 28-34
110. Wang, Xu J., Rottinghaus G.E., Simonyi A., Lubahn D., Sun G.Y., and Sun A.Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 958 (2002) 439-447
111. Wenzel E., and Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 49 (2005) 472-481
112. Wenzel E., Soldo T., Erbersdobler H., and Somoza V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res. 49 (2005) 482-494
113. Williams R.J., Spencer J.P., and Rice-Evans C. Flavonoids: antioxidants or signalling molecules?. Free Radical Biol. Med. 36 (2004) 838-849
114. Williamson G., and Manach C. Bioavailability and bioefficacy of polyphenols in humans: II. Review of 93 intervention studies. Am. J. Clin. Nutr. 81 suppl. 1 (2005) 243S-255S
115. Wood J.G., Rogina B., Lavu S., Howitz K., Helfand S.L., Tatar M., and Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430 (2004) 686-689 (Erratum in: Nature 431, 107)
116. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., and Mayo M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23 (2004) 2369-2380
117. You H., and Mak T.W. Crosstalk between p53 and FOXO transcription factors. Cell Cycle 4 (2005) 37-38
118. Zhuang H., Kim Y.S., Koehler R.C., and Dore S. Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann. N. Y. Acad. Sci. 993 (2003) 276-286 (May; discussion 287-288)
119. Zini R., Morin C., Bertelli A., Bertelli A.A., and Tillement J.P. Resveratrol-induced limitation of dysfunction of mitochondria isolated from rat brain in an anoxia-reoxygenation model. Life Sci. 71 (2002) 3091-3108